

Yevgeniy Samyshkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8885887/publications.pdf>

Version: 2024-02-01

24
papers

583
citations

623734

14
h-index

713466

21
g-index

24
all docs

24
docs citations

24
times ranked

967
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost-Effectiveness of Stroke Unit Care Followed by Early Supported Discharge. <i>Stroke</i> , 2009, 40, 24-29.	2.0	110
2	Estimating the impact of better management of glycaemic control in adults with Type 1 and Type 2 diabetes on the number of clinical complications and the associated financial benefit. <i>Diabetic Medicine</i> , 2016, 33, 1575-1581.	2.3	98
3	Cost-effectiveness of available treatment options for patients suffering from severe COPD in the UK: a fully incremental analysis. <i>International Journal of COPD</i> , 2012, 7, 183.	2.3	41
4	Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios. <i>Value in Health</i> , 2014, 17, 525-536.	0.3	41
5	Mental health reform in the Russian Federation: an integrated approach to achieve social inclusion and recovery. <i>Bulletin of the World Health Organization</i> , 2007, 85, 858-866.	3.3	37
6	Utilising artificial intelligence to determine patients at risk of a rare disease: idiopathic pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	35
7	Health systems efficiency in the Russian Federation: tuberculosis control. <i>Bulletin of the World Health Organization</i> , 2004, 84, 43-51.	3.3	27
8	Cost-effectiveness of roflumilast as an add-on treatment to long-acting bronchodilators in the treatment of COPD associated with chronic bronchitis in the United Kingdom. <i>European Journal of Health Economics</i> , 2014, 15, 69-82.	2.8	23
9	External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting. <i>Value in Health</i> , 2017, 20, 397-403.	0.3	23
10	Health system factors impacting on delivery of mental health services in Russia: Multi-methods study. <i>Health Policy</i> , 2006, 79, 144-152.	3.0	21
11	High levels of healthcare utilization prior to diagnosis in idiopathic pulmonary arterial hypertension support the feasibility of an early diagnosis algorithm: the SPHInX project. <i>Pulmonary Circulation</i> , 2018, 8, 1-9.	1.7	21
12	Cost-effectiveness of roflumilast in combination with bronchodilator therapies in patients with severe and very severe COPD in Switzerland. <i>International Journal of COPD</i> , 2013, 8, 79.	2.3	20
13	Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States. <i>Journal of Medical Economics</i> , 2012, 15, 654-663.	2.1	19
14	Costs and outcomes of tuberculosis control in the Russian Federation: retrospective cohort analysis. <i>Health Policy and Planning</i> , 2006, 21, 353-364.	2.7	16
15	Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis. <i>Journal of Medical Economics</i> , 2011, 14, 207-216.	2.1	13
16	Health system frailties in tuberculosis service provision in Russia: an analysis through the lens of formal nutritional support. <i>Public Health</i> , 2005, 119, 837-843.	2.9	12
17	Patient Heterogeneity in Health Economic Decision Models for Chronic Obstructive Pulmonary Disease: Are Current Models Suitable to Evaluate Personalized Medicine?. <i>Value in Health</i> , 2016, 19, 800-810.	0.3	11
18	Mental Health Care Reforms in Europe: Rehabilitation and Social Inclusion of People With Mental Illness in Russia. <i>Psychiatric Services</i> , 2010, 61, 222-224.	2.0	8

#	ARTICLE	IF	CITATIONS
19	Belantamab mafodotin for the treatment of relapsed/refractory multiple myeloma in heavily pretreated patients: a US cost-effectiveness analysis. <i>Expert Review of Hematology</i> , 2021, 14, 1137-1145.	2.2	3
20	Feasibility Study of a Network Meta-Analysis and Unanchored Population-Adjusted Indirect Treatment Comparison of Niraparib, Olaparib, and Bevacizumab as Maintenance Therapies in Patients with Newly Diagnosed Advanced Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1285.	3.7	3
21	Budget Impact of Belantamab Mafodotin (Belamaf) Adoption in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma in the United States. <i>ClinicoEconomics and Outcomes Research</i> , 2021, Volume 13, 789-800.	1.9	1
22	External validation of exacerbation and mortality outcomes of health economic decision models for COPD. , 2016, , .		0
23	Real world data from hospital episode statistics can be used to determine patients at risk of idiopathic pulmonary arterial hypertension. , 2018, , .		0
24	366â€¦Feasibility study of a network meta-analysis and unanchored population-adjusted indirect treatment comparison of niraparib, olaparib, and bevacizumab as maintenance therapies in patients with newly diagnosed advanced ovarian cancer. , 2020, , .		0